Omalizumab therapy for bullous pemphigoid.

Autor: Yu KK; Keck School of Medicine, University of Southern California, Los Angeles, California., Crew AB; Keck School of Medicine, University of Southern California, Los Angeles, California., Messingham KA; Carver College of Medicine, University of Iowa, Iowa City, Iowa., Fairley JA; Carver College of Medicine, University of Iowa, Iowa City, Iowa; Department of Veterans Affairs Medical Center, Iowa City, Iowa., Woodley DT; Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Veterans Affairs Medical Center, Los Angeles, California. Electronic address: dwoodley@usc.edu.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2014 Sep; Vol. 71 (3), pp. 468-74. Date of Electronic Publication: 2014 Jun 20.
DOI: 10.1016/j.jaad.2014.04.053
Abstrakt: Background: Bullous pemphigoid (BP) responds to a variety of immunosuppressive agents and usually controls, but does not cure, the disease. Omalizumab, Food and Drug Administration-approved for asthma, selectively suppresses the activity of IgE, an important immunoglobulin in the pathogenesis of BP.
Objective: We wished to determine if systemic omalizumab would have a therapeutic effect in patients with BP.
Methods: We treated 6 patients with BP using omalizumab and followed up their disease for up to 42 months.
Results: Although variable, 5 of the 6 patients with BP received therapeutic benefit from systemic omalizumab (the sixth terminated treatment because of intercurrent illness) with less use of other immunosuppressants, inhibition of new bullae, less pruritus, and dramatic decreases in eosinophil counts. None of the patients had untoward side effects from omalizumab.
Limitations: This was an open, uncontrolled study.
Conclusions: Omalizumab neutralizes the activity of IgE in patients with BP and improves the control of their disease activity.
(Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: